- Field Trip Health (FTRP) announces a C$50 million bought deal offering
- The deal establishes a price per share of C$6.50 with a total of 7,692,310 common shares changing hands
- The company intends to use the proceeds to open new health centers and to further develop the FT-104 novel psychedelic development program
- The offering is scheduled to close on or about March 16, 2021
- Field Trip is a global leader in the development and delivery of psychedelic therapies
- Field Trip Health (FTRP) is trading steady at C$8.00 per share
Field Trip Health (FTRP) announces a C$50 million bought deal offering of its common shares.
The company has entered into an agreement with Bloom Burton Securities, on behalf of a syndicate of underwriters, to purchase on a bought-deal basis 7,692,310 common shares at a price of C$6.50 per share for gross proceeds of C$50,000,015.
Field Trip intends to use the proceeds from the offering for the ongoing development of the FT-104 novel psychedelic development program, the opening of new Field Trip Health centers, and for working capital and general corporate purposes.
The offering is scheduled to close on or about March 16, 2021.
The company has granted the underwriters an over-allotment option to purchase up to 15% of the common shares sold pursuant to the offering at the issue price.
The common shares have not been, nor will they be, registered under the United States Securities Act of 1933.
Field Trip is a global leader in the development and delivery of psychedelic therapies. Its Field Trip Discovery division leads the development of the next generation of psychedelic molecules and conducts advanced research on plant-based psychedelics. Its Field Trip Health division builds centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale.
Field Trip Health (FTRP) is trading steady at C$8.00 per share as of 1:50 pm EST.
